Renal comorbidity in psoriatic arthritis patients

1. Ogdie, A., Schwartzman, S. & Husni, M.E. (2015). Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol, 27(2), 118-126. doi: 10.1097/BOR.0000000000000152.10.1097/BOR.000000000000015225603040Search in Google Scholar

2. Baker, J.F., Krishnan, E., Chen, L. & Schumacher, H.R. (2005). Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med, 118(8), 816-826. doi: 10.1016/j.amjmed.2005.03.043.10.1016/j.amjmed.2005.03.04316084170Search in Google Scholar

3. Bruce, I.N., Schentag, C.T. & Gladman, D.D. (2000). Hyperuricemia in psoriatic arthritis: prevalence and associated features. J Clin Rheumatol, 6(1), 6-9..10.1097/00124743-200002000-00001Search in Google Scholar

4. Peluso, R., Iervolino, S., Vitiello, M., Bruner, V., Lupoli, G. & Di Minno, M.N. (2015). Extra-articular manifestations in psoriatic arthritis patients. Clin Rheumatol, 34(4), 745-753. doi: 10.1007/s10067-014-2652-9.10.1007/s10067-014-2652-924803233Search in Google Scholar

5. Casals-Sanchez, J.L., Garcia De Yebenes Prous, M.J., Descalzo Gallego, M.A., Barrio Olmos, J.M., Carmona Ortells, L., Hernandez Garcia, C., & Grupo de Estudio em, A.R., II. (2012). Characteristics of patients with spondyloarthritis followed in rheumatology units in Spain. emAR II study. Reumatol Clin, 8(3), 107-113. doi: 10.1016/j.reuma.2012.01.006.10.1016/j.reuma.2012.01.00622465418Search in Google Scholar

6. Alenius, G.M., Stegmayr, B.G., & Dahlqvist, S.R. (2001). Renal abnormalities in a population of patients with psoriatic arthritis. Scand J Rheumatol, 30(5), 271-274.10.1080/03009740175318034511727841Search in Google Scholar

7. Ogdie, A., Schwartzman, S., Eder, L., Maharaj, A.B., Zisman, D., Raychaudhuri, S.P., Reddy, S.M. & Husni, E. (2014). Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations. J Rheumatol, 41(11), 2315-2322. doi: 10.3899/jrheum.140882.10.3899/jrheum.14088225362717Search in Google Scholar

8. Widemann, B.C. & Adamson, P.C. (2006). Understanding and managing methotrexate nephrotoxicity. Oncologist, 11(6), 694-703. doi: 10.1634/theoncologist.11-6-69410.1634/theoncologist.11-6-69416794248Search in Google Scholar

9. Dervisoglu, E., Akturk, A.S., Yildiz, K., Kiran, R. & Yilmaz, A. (2012). The spectrum of renal abnormalities in patients with psoriasis. Int Urol Nephrol, 44(2), 509-514. doi: 10.1007/s11255-011-9966-1.10.1007/s11255-011-9966-121505751Search in Google Scholar

10. Chiu, H.Y., Huang, H.L., Li, C.H., Yin, Y.J., Chen, H.A., Hsu, S.T., Lin, S.J., Tsai, T.F. & Ho, S.Y. (2015). Increased risk of glomerulonephritis and chronic kidney disease in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. Br J Dermatol, 173(1), 146-154. doi: 10.1111/bjd.1359910.1111/bjd.1359925511692Search in Google Scholar

11. Rodrigues, C.E., Vieira, W.P., Bortoluzzo, A.B., Goncalves, C.R., da Silva, J.A., Ximenes, A.C., Bertolo, M.B., Ribeiro, S.L., Keiserman, M., Menin, R., Skare, T.L., Carneiro, S., Azevedo, V.F., Albuquerque, E.N., Bianchi, W.A., Bonfiglioli, R., Campanholo, C., Carvalho, H.M., Costa, I.P., Duarte, A.P., Kohem, C.L., Leite, N.H., Lima, S.A., Meirelles, E.S., Pereira, I.A., Pinheiro, M.M., Polito, E., Resende, G.G., Rocha, F.A., Santiago, M.B., Sauma Mde, F., Valim, V. & Sampaio-Barros, P.D. (2012). Low prevalence of renal, cardiac, pulmonary, and neurological extra-articular clinical manifestations in spondyloarthritis: analysis of the Brazilian Registry of Spondyloarthritis. Rev Bras Reumatol, 52(3), 375-383..Search in Google Scholar

12. Feldman, S.R., Zhao, Y., Shi, L., Tran, M.H. & Lu, J. (2015). Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis. Arthritis Care Res (Hoboken), 67(5), 708-717. doi: 10.1002/acr.2249210.1002/acr.22492502958925303478Search in Google Scholar

13. Keith, D.S., Nichols, G.A., Gullion, C.M., Brown, J.B. & Smith, D.H. (2004). Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med, 164(6), 659-663. doi: 10.1001/archinte.164.6.659.10.1001/archinte.164.6.65915037495Search in Google Scholar

14. Foley, R.N., Murray, A.M., Li, S., Herzog, C.A., McBean, A.M., Eggers, P.W. & Collins, A.J. (2005). Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol, 16(2), 489-495. doi: 10.1681/ASN.2004030203.10.1681/ASN.200403020315590763Search in Google Scholar

15. National Kidney Foundation (2012). KDOQI clinical practice guidelines for glomerulonephritis Kidney Int.; 2(suppl 2):209-233Search in Google Scholar

16. Pana, C., Tuta, L., Hanzu-Pazara, L. & Suta, M. (2015) Association between inflammation and renal involvement in psoriatic arthritis Nephrol. Dial. Transplant. 30 (suppl 3): iii519Search in Google Scholar

17. Chi, C.C., Wang, J., Chen, Y.F., Wang, S.H., Chen, F.L. & Tung, T.H. (2015). Risk of incident chronic kidney disease and end-stage renal disease in patients with psoriasis: A nationwide population-based cohort study. J Dermatol Sci, 78(3), 232-238. doi: 10.1016/j.jdermsci.2015.03.01210.1016/j.jdermsci.2015.03.01225862150Search in Google Scholar